Squamous Cell Carcinoma
Conditions
Keywords
phase II/III, upper aerodigestive tract carcinoma, re irradiation, Recurrent or second upper aerodigestive tract carcinoma
Brief summary
Patients will be randomised after surgery, provided surgery is macroscopically adequate, that there is a flap of tissue protecting the vascular axis and that wound healing allows reirradiation to begin less than 8 weeks after surgery.Reirradiation will begin in the two arms less than 8 weeks after surgery in the irradiated area. The reirradiated volume : tumour bed + a safety margin of \< 2 cm with immediate protection of bone marrow. This volume should be jointly defined by the radiotherapist and the surgeon. During reirradiation, 60 Gy will be delivered in the two arms but will last 11 weeks in the reference arm and 5 weeks in the investigational arm.Acute toxicity (NCI-CTCAE) will be evaluated at the end of reirradiation and at 6 months from randomization (first follow-up consultation)
Interventions
RADIATIONsingle-fraction radiotherapy with concomitant 5FU and Hydrea
single-fraction radiotherapy with concomitant 5FU and Hydrea
RADIATIONhyperfractionated radiotherapy with concomitant Cetuximab
hyperfractionated radiotherapy with concomitant Cetuximab
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Ministry of Health, France
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Recurrent or second upper aerodigestive tract carcinoma in an area previously irradiated at a dose of \>= 50 Gy * Squamous cell carcinoma * No grade III or IV sequels linked to the first radiation therapy (excepted radiation sequels of salivary glands) * Relapse or second carcinoma (clinically invasive and/or lymph node recurrence \>= 3 cm and/or the association of a local and lymph node recurrence * Oral cavity, pharynx, larynx (if rT4), cervical region (if \>3cm) * No distant metastases confirmed by chest CT scan, abdominal ultrasound (or CT scan) in case of abnormal liver function, and bone scintigraphy in case of local symptoms * Surgery in the previously irradiated region allowing a macroscopically adequate resection * Surgery and vascular protection with a myocutaneous or free flap * Interval \> = 6 months between the end of the first radiation treatment and surgery in the previously irradiated area * Wound healing allowing reirradiation within an interval of 8 weeks after surgery in the previouly irradiated area. * No participation in a clinical trial during the 30 days preceding inclusion * Age between 18 et 70 years. * Performance Status 0 or 1 according to WHO criteria. * Hematological function : neutrophils \* 2 x 106/l, platelets : \* 100 x 106/l, hemoglobin : \* 10 g/dl (or 6.2 mmol/l) * Liver function : total bilirubin (normal) ; ASAT (SGOT) and ALAT (SGPT) \* 2.5 \* upper limit of normal (ULN) in each centre ; alkaline phosphatases \* 5 \* ULN. Patients whose ASAT or ALAT levels \> 1.5 \* ULN associated with alkaline phosphatases \* 2.5 \* ULN are not eligible for the trial * Renal function : serum creatinine \* 120 \*mol/l (1.4 mg/dl) ; if creatinine level is \> 120 \*mol/l, creatinine clearance should be \* 60 ml/min. * Written consent of participants
Exclusion criteria
* Superficial recurrence not associated with a lymph node relapse, isolated lymph node recurrence measuring less than 3 cm * Distant metastases * Grade 3 or 4 sequels of first radiation therapy (excepted salivary gland sequels) * Macroscopically inadequate surgery * Delay in wound healing obliging reirradiation to be postponed beyond 8 weeks. * \> Grade 3 Toxicity induced by chemotherapy administered during a previous treatment * Hypersensitivity to Erbitux * Concomitant severe comorbidities (non exhaustive list) * Unstable cardiac comorbidity in spite of treatment. * Neurological or psychiatric history such as dementia, convulsions. * Severe uncontrolled infection * Obstructive bronchopneumopathy which required hospitalisation during the year preceding inclusion. * Factors (psychological, familial, social or geographic) likely to hinder patient compliance with the study protocol and follow-up are considered
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute toxicity requiring an interruption of radiotherapy for more than 2 weeks | 6 months |
| Overall survival at 3 years and loco-regional control at 3 years | 3 years |
Countries
France
Outcome results
None listed